GPT and Hepatic steatosis: We observed that the administration of rmFGF21 (1 mg/kg/day) for 10 days (Figure S3A) decreased serum ALT (Figure S3B,D) and serum AST (Figure S3C,E) and attenuated various manifestations of hepatic steatosis, including liver weight gain (Figure 4A–D) and increased vacuolization/lipid accumulation (Figure 4E).